Major Finding: Patients with Parkinson's disease who received early treatment with pramipexole had a mean UPDRS score only 0.4 points different from patients who initiated treatment 6-9 months later.
Data Source: Phase I/II study on 535 patients with Parkinson's disease.
Disclosures: The study was sponsored by Boehringer Ingelheim. Dr. Schapira reported no relevant disclosures.
PREVIEW